Galmed Pharmaceuticals
152 articles about Galmed Pharmaceuticals
-
Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023
4/4/2024
Galmed Pharmaceuticals Ltd. announced that it has filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2023, with the U.S. Securities and Exchange Commission.
-
Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis
3/15/2024
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company") announced today the grant of a European patent related to the use of a combination of Aramchol and Resmetirom (MGL-3196, REZDIFFRA) for the treatment of NASH/MASH and liver fibrosis.
-
Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a Study
11/20/2023
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic diseases, announced today a delay of at least 6 months in the initiation of its Primary Sclerosing Cholangitis (PSC) Ph 2a Study.
-
Galmed Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal Fibrosis
9/26/2023
Galmed Pharmaceuticals Ltd. announced today the allowance of a Japanese patent related to treatment of pulmonary and dermal fibrosis.
-
Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification - September 22, 2023
9/22/2023
Galmed Pharmaceuticals Ltd. announced that the Company received a letter from the Nasdaq Listing Qualifications, indicating that the Company is not in compliance with the minimum bid price requirement for continued listing set forth in Listing Rule 5550, which requires listed securities to maintain a minimum bid price of $1.00 per share.
-
Galmed Pharmaceuticals Announces Pricing of $7 Million Public Offering
7/14/2023
Galmed Pharmaceuticals Ltd. announced today that it has entered into securities purchase agreements with two institutional investors to purchase 5,600,000 of its ordinary shares (or pre-funded warrants to purchase 5,600,000 ordinary shares at a combined purchase price of $1.25 per ordinary share and accompanying warrant (the "Offering").
-
Galmed to employ OnKai's disruptive Artificial Intelligence (AI) in its Planned Phase 2a Clinical Trial in PSC
7/10/2023
Galmed Pharmaceuticals Ltd. is delighted to announce the first step in its strategic partnership with OnKai, where OnKai will apply its artificial intelligence (AI), models for enrollment and execution of clinical trials in underserved communities, starting with Galmed's innovative Primary Sclerosing Cholangitis (PSC) clinical development program.
-
Galmed Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent Developments
6/1/2023
Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver and fibro-inflammatory diseases reports financial results for the three months ended March 31, 2023 and recent developments
-
Galmed Announces Initiation of a Clinical Development Program to Evaluate Aramchol meglumine for the Treatment of Primary Sclerosing Cholangitis (PSC)
5/9/2023
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic diseases, announced the initiation of a new clinical program to evaluate its lead compound, Aramchol meglumine for the Treatment of Primary Sclerosing Cholangitis.
-
Galmed Pharmaceuticals forms a Strategic Partnership with OnKai
5/4/2023
Galmed Pharmaceuticals Ltd. reported the execution of a definitive agreement for a $3M equity investment in OnKai Inc., leading an investment round of $6M.
-
Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2022
3/29/2023
Galmed Pharmaceuticals Ltd. announced that it has filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2022, with the U.S. Securities and Exchange Commission.
-
Galmed Announces Issuance of New Composition of Matter Patent for Aramchol meglumine Salt
2/8/2023
Galmed Pharmaceuticals Ltd. today that the United States Patent and Trademark Office (USPTO) granted Galmed United States Patent 11,571,431 B2, which is expected to provide exclusivity of Aramchol meglumine salt until December 2034.
-
Galmed announces positive late-stage results in biopsy-proven NASH patients.
-
Galmed reports results from the Open-Label part of the ARMOR study showing improvements in histology, imaging, and biomarkers with Aramchol
1/4/2023
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases reported full results from the Open-Label Part of the ARMOR study corroborating effects of Aramchol across all efficacy parameters.
-
Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) Announces Receipt of Extension to Meet the Nasdaq's Minimum Bid Price Requirement
12/14/2022
Galmed Pharmaceuticals Ltd., a biopharmaceutical company focused on the development of Aramchol and Amilo-5MER, announced that on December 13, 2022, it received a letter from The Nasdaq Stock Market LLC, notifying the Company that it is eligible for an additional 180 calendar day period, or until June 12, 2023, to regain compliance with the Nasdaq's minimum $1 bid price per share requirement.
-
Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results
8/4/2022
Galmed Pharmaceuticals Ltd. provides today a business update and reports financial results for the three and six months ended June 30, 2022.
-
Galmed Reports Significant Anti-Fibrotic Effects of Aramchol in a Lung Fibrosis Model
7/7/2022
Galmed Pharmaceuticals Ltd. announced today results showing significant effects of Aramchol in pre-clinical model of both lung and gastrointestinal (GI) fibrosis.
-
Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification
6/17/2022
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic, fibrosis and inflammatory diseases today announced that the Company received a letter from the Nasdaq Listing Qualifications (the "Letter").
-
Galmed updates business and clinical development strategy to better leverage Aramchol's anti-fibrotic effects
5/17/2022
Galmed updates business and clinical development strategy to better leverage Aramchol's anti-fibrotic effects.
-
Galmed Pharmaceuticals Reports First Quarter 2022 Financial Results
5/17/2022
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic, fibrosis and inflammatory diseases reports financial results for the three months ended March 31, 2022.